On January 19, 2024 Starpharma (ASX: SPL, OTCQX: SPHRY) reported the presentation of the positive results from its Phase 2 clinical trial of DEP cabazitaxel at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal (GI) Cancers Symposium[1], which is being held from 18 to 20 January 2024 in San Francisco, US (Press release, Starpharma, JAN 19, 2024, View Source;mc_eid=bf52dd3418 [SID1234639337]). ASCO (Free ASCO Whitepaper) is the world’s leading professional organisation for physicians and oncology professionals. The ASCO (Free ASCO Whitepaper) GI Cancers Symposium is the only global meeting of its kind focusing on the latest innovative science and clinical developments in GI cancer treatment, research, and care. It brings together oncology thought leaders, practising clinicians, novel drug developers, and GI specialists from around the world.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma’s scientific poster presents the key results from the Phase 2 trial of DEP cabazitaxel in patients with advanced gastro-oesophageal cancers, announced on 18 October 2023[2], and additional efficacy data for DEP cabazitaxel in two subgroups of the gastro-oesophageal cohort with different types of cancers: adenocarcinoma and squamous cell carcinoma (SCC). DEP cabazitaxel achieved disease control rates of 100% and 50%, respectively, in these advanced and typically hard-to-treat gastro-oesophageal cancers, which have a one-year survival rate of approximately 20%[3],[4].

The ASCO (Free ASCO Whitepaper) GI Cancers Symposium poster will be presented by Associate Professor David Pinato, a leading Clinician Scientist and Consultant Medical Oncologist at the Imperial College London and an investigator for the DEP cabazitaxel study.

Associate Professor David Pinato, MD, MRCP (UK), MRes, PhD, Clinical Reader and Consultant Medical Oncologist, Director of Developmental Cancer Therapeutics Imperial College London, and Investigator for the trial, said:

"I am excited to share the impressive data on Starpharma’s novel dendrimer formulation of cabazitaxel with the gastrointestinal cancer community at this specialist ASCO (Free ASCO Whitepaper) GI cancers conference.

"DEP cabazitaxel showed very encouraging efficacy signals in hard-to-treat gastro-oesophageal cancers, in addition to prostate cancer and advanced platinum-resistant ovarian cancer. The patients in this trial had a poor prognosis with few treatment options remaining.

"In the study, DEP cabazitaxel was well tolerated, including in patients with high-risk clinical features. A number of our patients experienced reduced cancer-related pain, leading to reduced opiate usage, and other improvements in quality of life.

"Based on the data and my experience with DEP cabazitaxel, it represents a well-tolerated and promising treatment alternative for gastro-oesophageal cancers, with the benefit of less frequent treatment than the standard-of-care taxane option."

The key results from the Phase 2 trial of DEP cabazitaxel demonstrated highly encouraging anti-tumour activity in advanced gastro-oesophageal cancers in multiple anatomic locations (oesophagus, gastro-oesophageal junction and stomach), including a median progression-free survival (PFS) of 4.0 months and a median overall survival (OS) of 8.6 months.

The results for DEP cabazitaxel in advanced gastro-oesophageal cancers compare very favourably to standard-of-care paclitaxel treatment in patients with oesophageal or gastro-oesophageal junction cancers. DEP cabazitaxel achieved clinically meaningful improvements with a more than 50% longer median progression-free survival and a 29% longer median overall survival than published data on paclitaxel administered weekly as a second-line treatment[5].

Despite the majority of patients with gastro-oesophageal cancer in Starpharma’s study being refractory to first-line therapy, DEP cabazitaxel achieved a disease control rate (DCR) of 80% and an objective response rate (ORR) of 30%, including stable disease (SD) for up to 27 weeks and partial responses (PR) for up to 17 weeks in evaluable gastro-oesophageal cancer patients.

The DEP cabazitaxel efficacy results in gastro-oesophageal cancer patients, along with highly encouraging efficacy results in patients with metastatic castrate-resistant prostate cancer and platinum-resistant ovarian cancer, indicate the promising clinical potential of DEP cabazitaxel in multiple cancer types, including cancers for which conventional cabazitaxel is not indicated[6].

As reported previously, DEP cabazitaxel was also well-tolerated, with most treatment-related adverse events (TRAEs) being mild to moderate (Grade 1/2, 83%).

Starpharma Chief Executive Officer, Cheryl Maley, commented:

"We are pleased to present the data on DEP cabazitaxel in gastro-oesophageal cancers at the ASCO (Free ASCO Whitepaper) GI cancers meeting. Starpharma’s dendrimer platform has shown promise in multiple therapeutic areas, and the recent Phase 2 results have clinically validated the effectiveness and safety of Starpharma’s DEP technology, which is designed to improve the therapeutic benefits of drugs while minimising their side effects. We are encouraged by these results and the feedback from patients and clinical trial investigators, which underscore the potential of Starpharma’s DEP technology and its ability to improve treatment outcomes for patients."

View/download the ASX Announcement: DEP cabazitaxel data presentation at ASCO (Free ASCO Whitepaper) GI cancer meeting.

View/download the ASCO (Free ASCO Whitepaper) GI Cancer Symposium poster.

About DEP cabazitaxel

Developed by Starpharma, DEP cabazitaxel is a patented, dendrimer nanoparticle version of conventional cabazitaxel, which is marketed as Jevtana and widely used in the treatment of prostate cancer. Unlike standard cabazitaxel, DEP cabazitaxel is highly water soluble, does not contain toxic detergent-like excipients associated with anaphylaxis, and avoids the need for steroid pre-medication. In both preclinical and clinical studies, DEP cabazitaxel has shown an improved side effect profile, notably markedly reduced bone marrow toxicity demonstrated by lower rates of severe neutropenia, thrombocytopenia, and severe anaemia, which are all reportedly experienced by a significant proportion of patients treated with Jevtana.

On January 18, 2024 TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported the pricing of a public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants (Filing, 8-K, TransCode Therapeutics, JAN 18, 2024, View Source [SID1234639411]). The warrants will have an exercise price of $1.22 per share, will be exercisable immediately upon issuance and will expire three and one-half years from the date of issuance. The closing of the offering is expected to occur on or about January 22, 2024, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be $7.25 million. The Company intends to use the net proceeds from this offering for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigational new drug (IND) enabling studies, and for working capital and other general corporate purposes.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-276467), which was declared effective by the Securities and Exchange Commission (the "SEC") on January 18, 2024. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at View Source and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On January 18, 2024 Alaya.bio, a biotechnology company developing a novel polymeric delivery platform towards in situ cell therapies, reported a collaboration with CAR-T pioneer Michel Sadelain, MD, PhD, Stephen and Barbara Friedman Chair and Director, Center for Cell Engineering at the Memorial Sloan Kettering Cancer Center (MSK) in New York City (Press release, Memorial Sloan-Kettering Cancer Center, JAN 18, 2024, https://www.businesswire.com/news/home/20240118114142/en/Alaya.bio-announces-significant-collaboration-with-leading-global-cancer-center-to-advance-in-situ-CAR-T-Therapy [SID1234639347]). The collaboration will advance research into in situ CAR-T cell therapies and evaluate their potential to deliver faster, more effective, and cost-efficient treatments for patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sadelain will join Alaya.bio as a scientific co-founder. The collaboration with the Sadelain lab includes a license agreement and a sponsored research agreement. Over the coming two years the Sadelain lab will lead activities to advance Alaya.bio’s polymeric delivery platform into the clinic in a chosen hematological malignancy.

Alaya.bio is developing a unique in situ CAR solution. While offering tremendous promise, traditional ex vivo CAR therapies suffer from significant complexity, long manufacturing cycles and high cost that still represent major hurdles to their widespread use. Alaya.bio’s proprietary polymeric in situ delivery platform is configured to meet the stringent demands of CAR therapy: its targeting agent, grafted onto the polymeric shell, precisely directs nanoparticles to T-cells, ensuring efficient and safe delivery of the therapeutic cargo. This innovative approach guarantees stable expression of the CAR transgene and preserves transduced T-cells from exhaustion, two crucial features for long-term clinical benefit.

Cécile BAUCHE, Ph.D., co-founder and CSO at Alaya.bio, emphasizes the privilege to collaborate with a world-leading institute, such as MSK and a CAR-T pioneer like Dr. Sadelain: "It is an immense pride that MSK and Dr. Sadelain decided to join forces to develop Alaya.bio’s in situ CAR-T platform."

"The ingenuity of Alaya.bio’s targeting polymeric nanoparticles has the potential to simplify and refine the development, manufacturing, and administration of CAR-T cell therapies in ways that expand applications and make them more accessible to patients," said Dr. Sadelain. "I am excited to leverage this technology and support its advancement on the frontiers of cell and gene therapy for patients."

Renaud Vaillant, co-founder and CEO at Alaya.bio, underscores, "Our collaboration with Dr. Sadelain will accelerate the validation of our novel polymeric delivery platform. In parallel, we will take advantage of our platform versatility, through partnering opportunities, to extend its use to adjacent therapeutic areas, while leveraging other innovative payloads like mRNA and gene editing technologies."

Renaud Vaillant will present information about this new collaboration at the MSK Life Sciences Innovation Showcase on January 26, 2024, in New York City.

On January 18, 2024 Novocure (NASDAQ: NVCR) reported that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug Administration (FDA) (Press release, NovoCure, JAN 18, 2024, View Source [SID1234639346]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to announce the FDA has accepted our PMA application for review of the LUNAR data in NSCLC," said Asaf Danziger, Novocure’s Chief Executive Officer. "This significant milestone brings us one step closer to treating patients seeking treatment for NSCLC, post-platinum, for which very few effective non-toxic options exist today. I would like to thank our investigators and patients, as well as our Novocure colleagues, for their dedication in pursuit of bringing our novel therapy to thousands of patients in need."

The PMA application for LUNAR was submitted with a filing date of December 15, 2023, and is now under substantive review by the FDA. Novocure expects to receive a regulatory decision from FDA in second half 2024.

About LUNAR

LUNAR tested the safety and effectiveness of TTFields therapy when used together with either an immune checkpoint inhibitor (ICI) or docetaxel for the treatment of patients diagnosed with metastatic NSCLC following progression on or after the use of platinum-based therapy. Patients randomized to receive TTFields therapy together with standard therapies (n=137) demonstrated median overall survival (OS) of 13.2 months compared to 9.9 months in patients treated with standard therapies alone (n=139). Patients randomized to receive TTFields therapy and physician’s choice ICI (n=66) demonstrated a median OS of 18.5 months versus a median OS of 10.8 months in patients treated with an ICI alone (n=68; HR=0.63; P=0.03). Patients randomized to receive TTFields therapy and docetaxel (n=71) had a positive survival trend with a median OS of 11.1 months vs 8.7 months in patients treated with docetaxel alone (n=71). TTFields therapy was well-tolerated with no added systemic toxicities and few grade 3 (no grade 4 or 5) device-related adverse events.

About NSCLC

Lung cancer is the most common cause of cancer-related death worldwide, and NSCLC accounts for approximately 85% of all lung cancers. It is estimated that approximately 193,000 patients are diagnosed with NSCLC each year in the U.S. Physicians use different combinations of surgery, radiation and pharmacological therapies to treat NSCLC, depending on the stage of the disease. Surgery, which may be curative in a subset of patients, is usually used in early stages of the disease. Since 1991, radiation with a combination of platinum-based chemotherapy drugs has been the first-line standard of care for locally advanced or metastatic NSCLC. Certain immune checkpoint inhibitors have been approved for the first-line treatment of NSCLC and the standard of care in this setting appears to be evolving rapidly. The standard of care for second-line treatment is also evolving and may include platinum-based chemotherapy for patients who received immune checkpoint inhibitors as their first-line regimen, docetaxel, immune checkpoint inhibitors or pemetrexed.

On January 18, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s 2024 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 18 – 20, 2024 in San Francisco, California (Press release, Natera, JAN 18, 2024, View Source [SID1234639345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Natera and its collaborators will present 11 abstracts that feature new Signatera data across various GI indications, including two oral presentations. An updated analysis from the previously published GALAXY study, the observational arm of the prospective CIRCULATE-Japan trial, will be presented in an oral presentation at the symposium and is also featured in ASCO (Free ASCO Whitepaper) GI’s press program. GALAXY is one of the largest and most comprehensive prospective studies of MRD testing in resectable colorectal cancer (CRC).

Additionally, the first read-out from the Natera-sponsored BESPOKE CRC study will be presented in a rapid oral presentation. BESPOKE CRC is the first large, prospective, US-based study in resectable CRC, with over 130 participating sites.

Highlights from the abstracts selected for oral presentation include:

Abstract ID: 6 | Oral Abstract Session C | CRC | Presenter: Hiroki Yukami, MD
Circulating tumor DNA (ctDNA) dynamics in CRC patients (pts) with MRD: Updated analysis from GALAXY study in CIRCULATE-JAPAN

This latest analysis from GALAXY included close to 3,000 stage I-IV CRC patients. Key findings include:

ctDNA dynamics at the six-month time point post-surgery showed that patients who remained ctDNA-positive were >6 times more likely to recur compared to those who cleared their ctDNA.
ctDNA-positive patients with sustained clearance in subsequent time points as a result of adjuvant chemotherapy (ACT) had remarkably better outcomes compared to those with transient ctDNA clearance (24-month DFS rate; 90.1% vs 2.3%) or no clearance (24-month DFS rate; 90.1% vs 2%).
In ctDNA-positive patients treated with ACT, a >50% decrease in ctDNA MTM/mL levels at six months, including those with complete clearances, was associated with better DFS than a <50% decrease or increase (24-month DFS rate; 51.1% vs 29%).
Abstract ID: 9 | Rapid Oral Abstract Session C | CRC | Presenter: Pashtoon Kasi, MD, MS
ctDNA for informing adjuvant chemotherapy (ACT) in stage II/III CRC: Interim analysis of BESPOKE CRC study

This analysis included 689 patients with stage II/III resectable CRC. Key findings include:

Within the ctDNA-positive cohort, patients receiving ACT had significantly longer DFS compared to those in the observation group (24-month DFS rate; 42.4% vs 12.5%). No benefit of ACT was observed in ctDNA-negative patients.
ctDNA monitoring allowed for oligometastases-directed therapy in 40% of patients who recurred.
A separate poster on the BESPOKE CRC study (abstract ID: 54) found that in 400+ patients surveyed, ≥92% valued the information received from their Signatera results or would use Signatera to guide their clinical care. In addition, 73% reported that Signatera results reduced anxiety about cancer recurrence.
"These latest findings from the landmark CIRCULATE trial underscore Signatera’s ability to identify patients who may be more likely to benefit from adjuvant chemotherapy, showing the value of personalized MRD testing to guide treatment decisions in CRC and potentially spare patients from unnecessary toxicity," said Hiroki Yukami, MD, from the Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, and lead study author of the GALAXY study. "We are encouraged by the widespread attention and recognition this presentation has received from the oncology community, and are optimistic that the GALAXY study, along with the ALTAIR escalation and VEGA de-escalation arms of CIRCULATE, will fundamentally change the way CRC is treated."

"We are pleased to share new data from the Japanese-based GALAXY and US-based BESPOKE CRC studies, which further demonstrate the prognostic and predictive power of longitudinal testing with Signatera in resectable colorectal cancer," said Minetta C. Liu, MD, chief medical officer of oncology at Natera. "These two prospective clinical trials provide strong evidence supporting the clinical utility of Signatera to inform adjuvant chemotherapy decisions and facilitate surveillance for cancer recurrence."

Below are the additional Natera poster presentations at ASCO (Free ASCO Whitepaper) GI:

Abstract ID: 54 | CRC | Presenter: Pashtoon Kasi, MD, MS
Patient-reported outcomes from the BESPOKE CRC study
Abstract ID: 27 | CRC | Presenter: Giulia Maddalena, MD
INTERCEPT Program of ctDNA Testing for MRD in CRC: Results from a Prospective Clinical Cohort
Abstract ID: 183 | CRC | Presenter: Hidekazu Oyoshi
Prediction of postoperative recurrence by integrating preoperative ctDNA levels and tumor metastasis volume in pts with CRC with resectable lung or liver metastasis
Abstract ID: 528 | Bile Duct Cancer | Presenter: Woo Jin Choi, MD, PhD
The role of pre-operative ctDNA in resectable intrahepatic cholangiocarcinoma
Abstract ID: 212 | Rectal Cancer | Presenter: Sakti Chakrabarti, MD
Prognostic value of ctDNA testing in rectal cancer pts after neoadjuvant therapy (NAT) and surgery
Abstract ID: 23 | CRC | Presenter: Masaaki Miyo, MD, PhD
Association of ctDNA MRD detection with lymph node metastasis after local excision of pathological T1 CRC: First results from DENEB, a CIRCULATE-Japan GALAXY substudy
Abstract ID: 196 | CRC | Presenter: Andrew Pellatt, MD
Redefining The Prognostic Significance of RAS and BRAF V600E Mutations on Disease Free Survival in CRC Pts in the Era of ct-DNA Defined MRD: Results from the MD Anderson INTERCEPT Program
Abstract ID: 695 | Pancreatic Cancer | Presenter: Ujwal Yanala, MD
Utility of ctDNA for the detection of MRD after curative-intent therapy for pts with localized pancreatic adenocarcinoma (PDAC): A single institution series and meta-analysis
Abstract ID: 214 | CRC | Presenter: Nikolas Naleid, MD
Surveillance of Resected Metastatic Colorectal Cancer Utilizing Circulating DNA
About Signatera

Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer (stage IIb and higher) and muscle invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 50 peer-reviewed papers.